Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study

著录项

• 来源
  《Allergy》 |2021年第4期|共11页
• 作者

  Lumry William R.; Weller Karsten; Magerl Markus; Banerji Aleena; Longhurst Hilary J.; Riedl Marc A.; Lewis Hannah B.; Lu Peng; Devercelli Giovanna; Jain Gagan; Maurer Marcus;

  展开▼
• 作者单位

  Allergy Asthma Res Associates Res Ctr Dallas TX USA;

  Charite Univ Med Berlin Dept Dermatol &

  Allergy Allergie Ctr Charite Dermatol Allergol Berlin;

  Charite Univ Med Berlin Dept Dermatol &

  Allergy Allergie Ctr Charite Dermatol Allergol Berlin;

  Harvard Med Sch Massachusetts Gen Hosp Div Rheumatol Allergy &

  Immunol Boston MA 02115 USA;

  Cambridge Univ Hosp NHS Fdn Trust Addenbrookes Hosp Cambridge England;

  Univ Calif San Diego Div Rheumatol Allergy &

  Immunol La Jolla CA 92093 USA;

  ICON Plc London England;

  Takeda Pharmaceut Co Ltd Lexington MA USA;

  Takeda Pharmaceut Co Ltd Lexington MA USA;

  Takeda Pharmaceut Co Ltd Lexington MA USA;

  Charite Univ Med Berlin Dept Dermatol &

  Allergy Allergie Ctr Charite Dermatol Allergol Berlin;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 医学免疫学;
• 关键词

  AEamp; 8208; QoL; hereditary angioedema; lanadelumab; longamp; 8208; term prophylaxis; quality of life;

  机译：AE＆amp;8208;QOL;遗传性血统密发药;Lanadelumab;Long＆amp;8208;术语预防;生活质量;